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Aim: Development of liposomal formulations of Cuphen, a potent copper-based 
aquaporin inhibitor with therapeutic potential against melanoma and colon cancer. 
Materials & methods: Cuphen was incorporated into liposomes using the dehydration–
rehydration method. The ability of Cuphen to induce cancer cell death was evaluated 
by MTS and ViaCount assays. In vivo toxicity studies were performed in BALB/c mice. 
Results: In vitro studies illustrated the antiproliferative effects of Cuphen in different 
cancer cell lines, in free form or after incorporation into liposomes. In vivo studies 
revealed no toxic effects after parenteral administration of Cuphen liposomes. 
Conclusions: Cuphen liposomes are highly attractive to be further tested in murine 
models due to the possibility of stabilizing and specifically deliver this metallodrug to 
tumor sites.
First submitted: 2 March 2016; Accepted for publication: 19 May 2016; Published 
online: 7 July 2016
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Introduction
Aquaporins (AQPs) are a family of small trans-
membrane proteins involved in the transport 
of water (orthodox AQPs) and small solutes 
such as glycerol (aquaglyceroporins), across 
the cell plasma membrane [1,2]. In mammals, 
13 different AQP isoforms (AQP0–12) can 
be found widely distributed throughout the 
body, playing several roles in different physi-
ological processes, such as urinary concentrat-
ing mechanism, glandular secretion or skin 
hydration. Some studies have demonstrated 
altered human AQP distribution and expres-
sion in pathological conditions and, thus, 
their modulation can be useful in treating 
human diseases. In the last decade, an increas-
ing number of reports showed that AQPs are 
abundantly expressed in different tumors and 
could serve as biomarkers with prognostic 
value of cancer aggressiveness [3–5].
AQPs are crucial for tissue water balance 
in response to osmotic gradients, essential to 
maintain cell function, including in malig-
nant cells. By facilitating water fluxes driven 
by an increase in local osmolarity due to trans-
membrane ion fluxes at the leading edge of 
the migrating cell, AQPs may facilitate tumor 
growth, local infiltration and metastasis. 
AQPs have also been associated with tumor 
proliferation through their ability to enable 
glycerol uptake that favors cellular energetic 
metabolism, biosynthesis and, consequently 
cell division [4,5]. Therefore, AQP expression 
can be advantageous for high metabolic turn-
over or tumor-specific metabolic pathways 
needed for survival of malignant cells.
As an example, the aquaglyceroporin 
AQP3 that is normally expressed in the skin 
with a role in skin hydration [6], was found to 
be overexpressed in cancerous human pros-
tate cells [7], primary squamous cell carcino-
mas [8] and in carcinogenesis and progression 
of several different carcinomas. In particular, 
Hara-Chikuma and Verkman have dem-
Nanoformulations of a potent copper-
based aquaporin inhibitor with cytotoxic 
effect against cancer cells
Mariana Nave1, Rui E Castro1, 
Cecília MP Rodrigues1, Angela 
Casini2, Graça Soveral**,1 & 
Maria Manuela Gaspar*,1
1Research฀Institute฀for฀Medicines฀
(iMed.ULisboa),฀Faculty฀of฀Pharmacy,฀
Universidade฀de฀Lisboa,฀Av.฀Prof.฀Gama฀
Pinto,฀1649-003฀Lisboa,฀Portugal 
2School฀of฀Chemistry,฀Cardiff฀University,฀
Park฀Place,฀Cardiff,฀CF10฀3AT,฀UK 
*Author฀for฀correspondence:฀ 
Tel.:฀+351฀217500767 
Fax:฀+351฀217946470 
mgaspar@ff.ulisboa.pt 
**Author฀for฀correspondence:฀ 
Tel.:฀+351฀217946461 
Fax:฀+351฀217946470 
gsoveral@ff.ulisboa.pt
For reprint orders, please contact: reprints@futuremedicine.com
10.2217/nnm-2016-0086 Nanomedicine (Lond.) (Epub ahead of print)
Figure 1. Chemical structures of the investigated gold(III) and copper(II) complexes.
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onstrated an aberrant AQP3 expression in skin car-
cinomas, while AQP3-null mice showed tumorigen-
esis resistance [9]. Although the mechanisms by which 
AQP3 interferes with cell differentiation and partici-
pates in tumorigenesis are not completely clear, they 
rely on AQP3 glycerol transport allowing increased 
ATP synthesis and promoting cell proliferation and 
tumor spread [9,10].
Due to the involvement of AQPs in cell migration, 
proliferation and adhesion in human cancer, these pro-
teins emerge as promising drug targets and their mod-
ulators as useful antitumor agents [11,12]. While there is 
still much to learn on the pathological processes arising 
from AQPs mutations or dysfunction, pharmacother-
apy via AQPs modulation was proposed as a valuable 
therapeutic strategy.
At present, there are few selective AQPs inhibitors 
described [11]. Moreover, the majority fails to undergo 
to clinical trials due to extreme toxicity. Recently, Mar-
tins et al. described new gold-based coordination com-
pounds as potent and selective inhibitors of the glyc-
erol transport through AQP3 in human red blood cells 
(hRBC) [13,14]. Interestingly, all these gold complexes 
contain N-donor ligands and are also described as anti-
proliferative agents against cancer cells in vitro [15–17]. 
Notably, no cytotoxic effect of the lead compound 
[Au(phen)Cl
2
] (phen=1,10-phenanthroline, Auphen, 
Figure 1) was observed for tumor cells that do not express 
AQP3 [18]. Furthermore, other gold complexes were also 
tested as potent inhibitors of cancer cells growth and 
they appeared as promising drug candidates [15,19].
Driven by these recent results regarding AQP3 
inhibition by gold compounds, in the present work a 
small library of potent and selective AQP3 metal-based 
inhibitors – including both gold(III) and copper(II) 
complexes (Figure 1) – were first tested against a 
human skin carcinoma cell line. Out of the obtained 
results, the copper-based complex [Cu(phen)Cl
2
] 
(Cuphen) was selected for subsequent in vitro experi-
ments. Hence, different human and murine cell lines 
were considered, aiming at establishing murine models 
of melanoma and/or colon cancer.
It is worth mentioning that several copper-based 
compounds have already been reported for their 
anticancer properties. In this context, the results by 
Ruiz et al. hold great promise, and include the group 
of metal compounds named casiopeinas, copper-based 
coordination complexes – containing a phenanthro-
line-type ligand and with generic structure of [Cu(N–
N)(O–N)]+ or [Cu(N–N)(O–O)]+ – that have proven 
to be cytotoxic to cancer cells, sensitive or resistant to 
cisplatin, to xenograph tumors in mice, and are now 
in clinical trials [20–23]. For these copper-based drugs, 
still the mechanism of action is not fully elucidated; 
most importantly, a number of side effects have been 
reported, including hematotoxicity [24]. In fact, Cu(II) 
ions bound to DNA react with H
2
O
2
 and ascorbic 
acid generating hydroxyl radicals, which immediately 
attack DNA bases in a site-specific manner, and thus 
the availability of Cu(II) ion in vivo may also be poten-
tially harmful.
The development of metallodrugs in the treatment 
of cancer has been hampered by the low efficiency of 
transport processes of their active species to biological 
targets. This has led to the design and development 
of novel technologies based on nanostructured materi-
als, acting mainly as vectors for metallodrug delivery 
or simply as protectors of active species of the com-
plexes for amplifying their activities and reducing their 
degradation [25,26]. In the case of anticancer copper 
complexes, few reports in the literature describe their 
delivery via TiO
2
 nanoparticles or via conjugation to 
phosphorus dendrimers [27].
To the best of our knowledge, no use of liposome 
formulations has been attempted so far for cytotoxic 
copper(II) complexes. Liposomes are widely recog-
nized the drug delivery system that may allow the min-
imization of drawbacks commonly presented by vari-
ous anticancer agents, including metallodrugs, such 
as drug instability and reactivity [28]. They are also 
able to protect the incorporated drugs from premature 
degradation/metabolization, while keeping their thera-
peutic activity [25,29–31]. In addition, liposomes mimic 
cellular membranes conferring biocompatibility and 
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biodegradability and may allow their accumulation at 
tumor sites characterized by impaired lymphatic func-
tion [32,33].
Taking into account that Cuphen presents a copper 
center with possible toxic effects, and in the process of 
stabilizing the metal compound for in vivo administra-
tion, the compound was first incorporated in different 
liposomes and the antiproliferative activity induced 
by the most promising formulations was evaluated 
against the same cancer cell lines in vitro. In addition, 
the blood toxicity of Cuphen and of its liposome for-
mulations was assessed, and preliminary in vivo studies 
were conducted to study the safety of liposomal for-
mulations for further therapeutic evaluation in cancer 
murine models.
Materials & methods
Chemical products
The metal complexes included in the present work 
were [Au(phen)Cl
2
] (phen=1,10-phenanthroline, 
Auphen), [Cu(phen)Cl
2
] (Cuphen) and two differ-
ent compounds of general structure [Au(bipy)Cl
2
]PF
6
 
(bipy = 2,2’-bipyridine, Aubipy, or 4,4’-dimethyl-2,2’-
bipyridine, AubipyMe) (Figure 1). Cuphen is commer-
cially available (Sigma-Aldrich), while the gold(III) 
complexes were prepared according to literature pro-
cedures [34,35]. The purity of the compounds was con-
firmed by NMR and elemental analysis, and all of 
them showed purity greater than 98%.
The pure phospholipids, egg phosphatidylcholine 
(ePC), dimyristoyl phosphatidylcholine (DMPC), 
dipalmitoyl phosphatidylcholine (DPPC) and dis-
tearoyl phosphatidylethanolamine covalently linked 
to poly(ethylene glycol) 2000 (PEG), used for the 
preparation of liposomal formulations were purchased 
from Avanti Polar Lipids (AL, USA). Deionized water 
(Milli-Q system; Millipore, Tokio) was used in all 
experiments. Nuclepore Track-Etch Membranes were 
purchased from Whatman Ltd (NY, USA). Culture 
media and antibiotics were obtained from Invitrogen 
(Life Technologies Corporation, NY, USA). Reagents 
for cell proliferation assays were purchased from Pro-
mega (WI, USA). Octadecylamine (n-Stearylamine 
[SA]), cholesterol (Chol) and Hoescht 33258 were pur-
chased from Sigma (Sigma-Aldrich, MO, USA). All 
the remaining chemicals and substrates used were of 
analytical grade.
Animals
Male BALB/c mice were obtained from Gulbenkian 
Institute of Science, Portugal. Animals were kept under 
standard hygiene conditions, fed commercial chow and 
given acidified drinking water ad libitum. All animal 
experiments were carried out with the permission of 
the local animal ethical committee of the Faculdade de 
Farmácia, Universidade de Lisboa in accordance with 
the EU Directive (2010/63/UE) and Portuguese laws 
(DR 113/2013).
Cell culture
Human epidermoid carcinoma (A431), human mela-
notic neuroectodermal tumor (MNT-1), human kera-
tinocytes (HaCaT) and murine melanoma (B16F10) 
cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) with high-glucose (4500 mg/l), 
supplemented with 10% fetal bovine serum and 100 μg/ml penicillin/streptomycin (Invitrogen). Murine 
colon cancer cells (C26) were maintained in RPMI 
1640 with the supplementation described above. All 
cell lines were kept at 37°C under a 5% CO
2
 atmo-
sphere. Maintenance of cultures was performed every 
2/3 days, until cells reached a confluence of about 
80%. Cells were seeded in 96-well plates at 7.5 × 103 
cells/well for MTS assays and in 24-well plates at 7.5 × 
104 cells/well for Guava ViaCount assays.
Cuphen quantification in liposomes
Cuphen was quantified by UV–Vis spectrophotometry 
at 272 nm. Linearity of calibration curves was ensured 
from 2 up to 20 μM (R² = 0.9983; Slope: 0.0331 ± 
0.0017; Y-intercept [x = 0]: 0.0001 ± 0.0020). The 
Cuphen liposomes quantification was preceded by 
liposome disruption with absolute ethanol.
Liposomes preparation
Liposomes composed of the selected phospholip-
ids were prepared by the dehydration–rehydration 
method [36] (Supplementary Figure S1). Three neutral 
phospholipids – ePC, DMPC and DPPC were used 
as major constituents of Cuphen liposomal formula-
tions. In order to play with membrane fluidity, Chol 
was included in the lipid composition. The addition 
of positively charged surfactant, SA, was also used and 
the influence of its presence in Cuphen incorporation 
parameters was compared with neutral nanoformula-
tions. In addition, as it is our intention to develop long 
circulating liposomes, another Cuphen liposomal for-
mulation containing in the lipid composition the poly-
mer PEG covalently linked to distearoylphosphatidyl 
ethanolamine was also prepared. All the nanoformula-
tions were prepared at an initial lipid concentration of 
20 μmol/ml.
Briefly, the selected phospholipids were dissolved 
in chloroform and the lipid solution was evapo-
rated (Buchi R-200 rotary evaporator, Switzerland) 
to obtain a thin lipid film in a round-bottom flask. 
The lipid film was then dispersed in a Cuphen aque-
ous solution (500 μM) and the so-formed suspension 
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was frozen (-70°C) and lyophilized (Freeze dryer, CO, 
USA) overnight.
The rehydration of the lyophilized powder was per-
formed with a buffer constituted of 10 mM HEPES 
and 145 mM NaCl, pH 7.4 (HEPES buffer) in two 
steps, in order to enhance the Cuphen incorpora-
tion [37]. The so-formed liposomal suspension was 
then filtered, under nitrogen pressure (10–500 lb/in2), 
through polycarbonate membranes of appropriate pore 
size (0.8, 0.6, 0.4 [3×], 0.2 [3×] and 0.1 [3×] μm) until 
an average vesicle size of 0.1 μm was obtained using an 
extruder device (Lipex: Biomembranes Inc., Vancouver, 
Canada). The separation of nonincorporated Cuphen 
was performed by ultracentrifugation at 250,000×g for 
120 min at 15°C in a Beckman LM-80 ultracentrifuge 
(Beckman Instruments, Inc, CA, USA). Finally, the 
pellet was suspended in HEPES buffer, according to 
the final concentration desired. Empty liposomes were 
also prepared with the same lipid compositions. After 
rotary evaporation, the lipid film was dispersed in 
HEPES buffer and submitted to the extrusion steps as 
previously referred.
Liposome characterization
Liposomes were characterized in terms of lipid com-
position and by the following incorporation parame-
ters: initial and final Cuphen to lipid ratios ((Cuphen/
Lip)i and (Cuphen/Lip)f, respectively) and incor-
poration efficiency (I.E.) defined as the percentage 
of [(Cuphen/Lip)f ]/[(Cuphen/Lip)i]. Cuphen was 
quantified spectrophotometrically at 272 nm (e = 
33,000 M-1 cm-1) after disruption of the liposomes 
with ethanol. Lipid content was determined using a 
colorimetric technique described by Rouser et al. [38]. 
Briefly, samples (in triplicate) containing phosphate 
quantities between 20 and 80 nmol (sample volume 
below 100 μl) were pipetted into 15-ml glass tubes. In 
parallel, a calibration curve with phosphate amounts 
ranging from 20 to 80 nmol was also pipetted in trip-
licate into glass tubes. All tubes were heated (180°C) 
in a heating block until dryness. After cooling, 
0.3 ml of perchloric acid (70–72%) was added to all 
tubes. In order to avoid volume losses, marbles were 
placed on the top of all glass tubes. At this point, all 
tubes were heated at 180°C for 45 min to convert 
all the organic lipid phosphate to the inorganic form. 
After cooling samples to room temperature, 1.0 ml 
of H
2
O, 0.4 ml of hexa-ammonium heptamolybdate 
solution [1.25% (w/v)] followed by 0.4 ml of ascor-
bic acid solution [5% (w/v)] were added to all glass 
tubes. A blue color solution was obtained due to the 
reduction of ascorbic acid during heating in a boiling 
water bath for 5 min. After cooling, the absorbance 
of all samples was recorded at 797 nm) in a UV-mini 
1240 spectrophotometer (Shimadzu). The amount of 
phosphate in samples was obtained through the cali-
bration curve with the aid of linear regression. The 
calibration curve was linear up to absorbance values 
of 1.0.
Liposomes mean size was determined by dynamic 
light scattering (Zetasizer Nano S [Zen 1600], Malvern 
Instruments, UK) at a standard laser wavelength of 
663 nm. The system also reports a polydispersity index, 
as a measure of particle size distribution, ranging from 
0.0 for an entirely monodisperse sample up to 1.0 for 
a polydisperse suspension (Supplementary Figure S2). 
Zeta potential of liposomal formulations was measured 
in a hydrodynamic sizing system (Zetasizer Nano Z 
[Zen 2600], Malvern Instruments).
Cell viability & cytotoxicity
Cell viability was evaluated in the absence (control) or 
the presence of increasing concentrations of Cuphen in 
free and liposomal forms studied by measuring mito-
chondrial activity, based on the colorimetric method 
of reducing the compound MTS (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium), included in the commer-
cial kit, from Promega Corporation (WI, USA). This 
method consists on the conversion of MTS salt and 
its reduction, within the mitochondria, to formazan 
crystals that are soluble in tissue culture. This com-
pound can be spectrophotometrically quantified and 
the respective absorbance values at 490 nm are propor-
tional to mitochondrial activity, and, consequently, to 
the number of living cells [39].
For the determination of cytotoxic effect of Cuphen 
in free and liposomal forms, cells at a concentration of 
7.5 × 103 cells/ml were placed in 96-well plates (200 μl) 
for 24 h in culture conditions specified above. After-
ward, culture medium was removed and adherent cells 
were treated with metallodrugs in free or in liposomal 
forms, at concentrations ranging from 0.25 to 60 μM 
for the initial cytotoxicity screening and 0.625 to 
20 μM for the subsequent experiments. Negative con-
trol was the cell line in the presence of culture medium. 
Unloaded liposomes constituted another control group, 
using the same lipid concentrations as in Cuphen lipo-
somes. The incubation periods were 48 and 72 h. After 
this period, the culture medium was removed from all 
wells and replaced with 100 μl of incomplete culture 
medium. Subsequently, 20 μl of MTS was added to 
all wells, agitated, followed by an incubation period of 
60 min, under the same culture conditions mentioned 
above. Absorbance was measured at 490 nm in a micro-
plate reader Model 680 (Bio-Rad, CA, USA). All mea-
surements were performed with six samples for each 
concentration tested.
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Figure 2. Concentration-dependent inhibition of A431 
cellular viability 72 h after incubation with different 
metallodrugs (MTS assay). Results are expressed as the 
mean percentage (%) of control ± SD.
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Guava ViaCount assay
ViaCount Assay distinguishes between viable and 
nonviable cells based on different permeability of two 
DNA-binding dyes in the Guava ViaCount® Reagent 
(Merck Millipore, Darmstadt, Germany). The nuclear 
dye stains only nucleated cells, while the viability dye 
brightly stains dying cells. MNT-1 cells were seeded in 
24-well plates (7.5 × 104 cells/well) and after 24 h they 
were incubated with Cuphen in free and liposomal 
forms for 72 h. After treatment, cell culture superna-
tants were collected and adherent cells were detached 
with TrypLE (Invitrogen). Subsequently, detached 
cells were added to the respective supernatant and cen-
trifuged for 5 min at 650×g. Supernatants were dis-
carded and cells were suspended in 30 μl of phosphate 
buffered saline (PBS) with 2% fetal bovine serum 
(FBS). On a 96-well plate, 15 μl of cell suspension was 
then incubated with 135 μl of Guava ViaCount reagent 
for 5 min at room temperature. Data acquisition and 
analysis were performed using the ViaCount software 
module on a Guava EasyCyte 5HT Flow cytometer 
(Guava Technologies, Inc, CA, USA) [40].
Hemolytic activity
The hemolytic activity of Cuphen in free and lipo-
somal forms as well as in unloaded liposomes was 
determined using EDTA-preserved peripheral human 
blood [41]. Human peripheral blood, EDTA-preserved, 
was obtained from voluntary donors and used in the 
same day of experiments. Serum was removed by cen-
trifugation at 1000×g for 10 min and the erythrocyte 
suspension was washed three-times in PBS at 1000×g 
for 10 min. All formulations under study were diluted 
in HEPES buffer. Cuphen concentrations ranging 
from 0.2 to 200 μM were distributed in 96-well plates 
(100 μl/well). Then, 100 μl of erythrocyte suspension 
was added to all samples, microplates were incubated 
at 37°C for 1 h and then centrifuged at 800×g for 
10 min. Absorbance of supernatants was measured at 
550 nm with a reference filter at 620 nm. The percent-
age of the hemolytic activity for each sample was cal-
culated comparing each individual determination to a 
100% hemolysis (erythrocytes in distilled water), posi-
tive control and negative control (erythrocytes in PBS) 
according to the mathematical formula:
(AbsS – AbsN)/(AbsN – AbsP) × 100, where AbsS 
is the Average absorbance of the sample, AbsN is the 
Average absorbance of the negative control and AbsP is 
the Average absorbance of the positive control.
In vivo toxicity profile in BALB/c mice
The toxicity of Cuphen in free and liposomal forms 
was evaluated in male BALB/c mice with the age of 
6–8 weeks. Groups of five mice each were injected 
intravenously (iv.) with formulations at a dose of 
1.5 mg/kg of body weight, three-times a week during 
1 week. The activity levels of animals were monitored 
in the analyzed period. Two days after the last injec-
tion, mice were sacrificed and blood and organs were 
collected and analyzed. The tissue index was  calculated 
according to the formula:
Statistical analysis
All data presented are expressed as mean ± standard 
deviation (SD) with the exception of the cytotoxicity 
results where data are presented as the best fit value ± 
standard error (SE) of at least three different experi-
ments. Statistical analysis was performed with the 
paired Student’s t-test or one-way analysis of variance 
(ANOVA) followed by Turkey’s test using GraphPad 
Prism version 5.00 for Windows, GraphPad Soft-
ware, CA, USA (www.graphpad.com). p < 0.05 was 
 considered  statistically significant.
Results & discussion
Antiproliferative effects of metal compounds 
in cancer cells
In a previous work, the antiproliferative effect of the 
gold(III) complex Auphen, with human AQP3 inhi-
bition properties, was demonstrated against a human 
skin carcinoma cell line A432 [18]. In an attempt to 
select other potential cytotoxic metallodrugs, also act-
ing as AQP3 inhibitors, an in vitro screening was per-
formed where the same epidermoid carcinoma A431 
cells were incubated for 72 h with Auphen, Cuphen, 
AubipyMe and Aubipy, with concentrations ranging 
from 0.250 up to 60 μM, and cell viability determined 
Tissue index
animal weight
organ weight
100#=
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Figure 3. Concentration-dependent inhibition of different cell lines, 72 h after incubation with Cuphen (A) in the 
free form or (B) incorporated in liposomes (Formulation 2) (MTS assay). Cuphen concentrations ranged from 0.625 
to 20 μM. Results are expressed as the mean percentage (%) of control ± SD.
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by the MTS assay as described in the Experimental sec-
tion. Dose-response curves are shown in Figure 2 and 
the IC
50
 values obtained from data fits are summarized 
in Table 1. Inhibition of glycerol permeability in hRBC 
by the same metal complexes [13,14] is also reported for 
comparison purposes.
As shown in Figure 2, the cellular behavior under the 
influence of the phenanthroline compounds (Auphen 
and Cuphen) differs significantly from the bipyridine 
cores (p <0.001). For the compound AubipyMe, only 
moderate cytotoxic effects were observed. Instead, 
the phenanthroline derivates, Auphen and Cuphen, 
display similar and significant cytotoxic effects with 
IC
50
 values in the low micromolar range. It is worth 
observing that part of its cytotoxic effect may be due 
to the intrinsic toxicity of this phenanthroline ligand, 
as already described in the literature [42]. In addition, 
Cuphen induces a decrease in cellular viability of 
approximately 80%, while Auphen is only capable of a 
65% reduction. Aubipy was not able to exert any toxic 
effect on the cellular viability even at the highest con-
centration of 60 μM. These differences on the cyto-
toxic profiles rely on the metal core, as well as on the 
differences in its stability with respect to both redox 
and ligand exchange reactions, also due to the ligands. 
Taking into account the results above, the cytotoxic 
potential of the studied metallodrugs, regarding this 
A431 cell line, can be represented in the following 
order: Cuphen>Auphen>AubipyMe.
In terms of possible mechanisms of action, it is 
important to highlight that copper–phenanthroline 
compounds are already described as potent inducers of 
oxidative DNA damage [43–45], and Cu2+ compounds, 
including Cuphen, are also reported as AQP3 inhibi-
tors (Table 1) [14,46].
Taking into account these cell viability results, 
and due to its promising AQP3 inhibition properties, 
Cuphen was selected to be tested in the following stud-
ies. Cuphen cytotoxic activity was evaluated against 
different mammalian cell lines, all representative of 
Table 1. Half-inhibitory concentration of metal compounds in cellular proliferation of A431 cells 
after 72 h incubation and inhibition of glycerol permeability in human red blood cells by the same 
metal complexes.
Compound Inhibition of cell viability Inhibition of glycerol permeation 
in hRBC* 
 IC
50
 ± SE (μM)
Auphen 3.7 ± 1.2 0.8 ± 0.1
Cuphen 3.0 ± 0.4 81.9 ± 4.1
Aubipy >60 2.3 ± 0.7
AubipyMe 14.9 ± 1.1 1.0 ± 0.4
hRBC:฀Human฀red฀blood฀cell;฀IC50:฀Half-inhibitory฀concentration;฀SE:฀Standard฀error.*Data฀taken฀from฀[13,14].
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cancer tissues where AQP3 overexpression has already 
been demonstrated: two human skin cancer cell 
lines, the A431 (epidermal carcinoma) [18,47] and the 
MNT-1 (melanotic neuroectodermal tumor) [48], as 
well as a nontumorigenic human keratinocyte cell line, 
HaCaT [49,50]. Aiming for possible future in vivo stud-
ies, two murine cell lines were also included: B16F10 
(for melanoma) [3] and C26 (for colon cancer) [51,52].
In this study, Cuphen proved to be effective by 
inhibiting cellular viability for all the evaluated cell 
lines in the range of the concentrations tested (from 
0.625 to 20 μM). All dose–response curves presented 
a similar profile with a maximum decrease on cellu-
lar viability of around 80%, except for the healthy cell 
line HaCaT showing only a 60% maximal reduction 
in viability (Figure 3A). The IC
50
 values determined are 
at the low micromolar range (<4 μM) (Table 2).
Cuphen proved to be highly cytotoxic against all 
the considered tumor cell lines with IC
50
 values around 
3 μM. It is worth noting that Cuphen was also cytotoxic 
against human healthy keratinocytes HaCaT, which 
was not surprising, since HaCaT cells also express 
AQP3 [50] although with lower levels than tumor cells. 
Thus, following these promising results and pursu-
ing the transposition for in vivo studies, liposomes 
 containing Cuphen were developed and characterized.
Characterization of Cuphen liposomes
Cuphen was incorporated in liposomes using the dehy-
dration–rehydration method followed by an extrusion 
step to reduce the mean size of the so-formed nano-
formulations [36,53,54]. Due to its hydrophilic proper-
ties, Cuphen is only added after formation of the lipid 
film. Following the lyophilization of the so-formed 
liposomal suspension, rehydration was performed 
with HEPES buffer in two steps, in order to increase 
Cuphen incorporation [37].
Cuphen liposomes were prepared with different 
lipid compositions, in other words, phospholipids of 
different phase transition temperatures (Tc), aiming to 
select the ones that were able to accommodate higher 
amounts of Cuphen per mol of lipid. Specifically, three 
neutral phospholipids – ePC (natural phospholipid), 
DMPC and DPPC (synthetic phospholipids) were 
used as major constituents of Cuphen nanoformula-
tions that present increasing Tc of -6, +23 and +41°C, 
respectively.
The first series of nanoformulations was based on 
the natural phospholipid ePC. Considering its high 
fluidity, Chol was included in the lipid composition to 
decrease the membrane permeability and consequently 
to enhance the stability of the incorporated Cuphen. 
The inclusion of positively charged surfactant, SA, was 
also used and the influence of its presence in Cuphen 
incorporation parameters was compared with neutral 
nanoformulations. In addition, as it is our purpose 
to develop long circulating liposomes, another set of 
lipid compositions containing distearoylphosphatidyl 
ethanolamine (PEG) was also prepared. In Table 3, the 
results obtained for different ePC Cuphen  formulations 
are summarized.
All ePC-Cuphen liposomes presented mean sizes 
ranging from 0.15 to 0.20 μm with polydispersion 
index below 0.15, evidencing the high homogeneity 
of all nanoformulations. In terms of loading capac-
ity, ePC formulations without Chol (F1 and F4) were 
able to accommodate high amounts of Cuphen per μmol of lipid with I.E. values of 54–61%, respectively. 
The inclusion of Chol in the lipid composition led to 
a decrease on incorporation parameters (F2 and F3). 
When included in the lipid composition of liposomes, 
Chol is inserted within bilayers, influencing membrane 
fluidity and competing with the accommodation of 
hydrophobic molecules. These findings are in accor-
dance with the literature [56,57] suggesting that despite 
its hydrophilic character, Cuphen, may also interact 
with the lipid bilayers, probably through the ligand 
phenanthroline, thus explaining the observed I.E. val-
ues. Interestingly, in the absence of PEG, all formula-
tions showed similar zeta potential values (-9 ± 1 mV). 
Table 2. Half–inhibitory concentration of Cuphen in the free form or after incorporation into 
liposomes (F1 and F2), 72 h after incubation in different cell lines.
Cell line IC
50
 ± SE (μM)
Free Cuphen F1 F2
HaCat 3.4 ± 0.2 5.3 ± 0.2 5.8 ± 0.1
MNT-1 3.1 ± 0.2 4.8 ± 0.2 4.4 ± 0.2
A431 2.7 ± 0.1 10.0 ± 0.8 8.3 ± 0.8
C26 1.8 ± 0.1 5.8 ± 0.4 4.4 ± 0.4
B16F10 3.3 ± 0.3 4.5 ± 0.2 5.1 ± 0.1
Lipid฀compositions:฀Formulation฀1:฀ePC;฀Formulation฀2:฀ePC:Chol:PEG. 
IC50:฀Half-inhibitory฀concentration.฀
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Figure 4. Influence of the bilayer rigidity on Cuphen 
incorporation parameters: I.E. (%) (white columns) and 
[Cuphen/Lip]f (gray columns). Comparison between ePC, 
DMPC and DPPC. Results are expressed as mean ± S.D. 
***p < 0.001.
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Even for F4, the inclusion of SA was not able to reduce 
the negative charge of liposomes. In order to clarify 
these observations, unloaded liposomes with the same 
lipid composition of F1 and F2 were prepared (Table 3). 
The results show no differences on the zeta potential 
values for ePC:Chol:PEG (-3 ± 1 mV), while the ePC-
unloaded liposomes displayed less negative values (-4 ± 
1 mV) than those observed in the presence of Cuphen 
(-9 ± 1 mV). The different physicochemical properties 
observed for F1 point out that Cuphen influences the 
superficial charge of the vesicles. In addition, nanofor-
mulations of ePC:SA and DMPC:SA with the same 
molar ratio incorporating Cuphen were prepared and 
compared regarding the superficial charge and I.E. val-
ues. The higher I.E., observed for ePC:SA, resulted in 
higher negative values for the zeta potential whereas for 
DMPC:SA the value was positive (+7 ± 1 mV) (data 
not shown). This finding reinforces the hypothesis of 
a possible insertion of Cuphen within the liposome 
membrane, even partial, justifying the changes of the 
 superficial charge when Cuphen is incorporated in ePC 
(F1).
The second set of nanoformulations was designed to 
evaluate the influence of the rigidity of the main neutral 
phospholipid on Cuphen incorporation parameters. For 
this purpose Cuphen liposomes were prepared with ePC, 
DMPC or DPPC, in other words, phospholipids with 
increased Tc. As shown in Figure 4, the increase in Tc of 
the phospholipid used, as major constituent of the lipid 
bilayer, led to a systematic decrease of Cuphen I.E. from 
54 to 6%. F1 and F2 were selected for pursuing in vitro 
tests, as they presented high incorporation parameters 
and long circulating properties, respectively. Although 
similar incorporation parameters were achieved for for-
mulation F4, it was not chosen for in vitro studies due to 
SA toxicity reported in the literature [58,59].
Cytotoxicity of Cuphen liposomes
The ability of Cuphen-loaded liposomes to induce cell 
death was evaluated by the MTS assay for all the cell 
lines and by the ViaCount assay for one selected cell 
line to validate results.
MTS assay
The incubation conditions for Cuphen liposomes 
were established in comparison to the cellular viabil-
ity at different time-points and by using Cuphen in 
the free form as a positive control (data not shown). 
In Figure 3B, the dose–response curves of cells incu-
bated for 72 h with PEG liposomes (F2) and differ-
ent concentrations of Cuphen (ranging from 0.625 to 
20 μM) are shown; while the calculated IC
50
 values 
Table 3. Physicochemical characterization of Cuphen liposomes.
Formulation Lipid composition 
(molar ratio)
 
Cuphen liposomes Unloaded liposomes
 (Cuphen/Lip)f 
(nmol/μmol) I.E. (%) Ø (μm) (PI) Zeta Pot. (mV) Ø (μm) (PI) Zeta Pot. (mV)
1 ePC 21 ± 7 54 ± 1 0.15 -9 ± 1 0.14 -4 ± 1
    (<0.15)  (0.1)  
2 ePC:Chol:PEG 15 ± 3 47 ± 5 0.16 -4 ± 1 0.14 -3 ± 1
 (1.85:1:0.15)   (<0.15)  (0.1)  
3 ePC:Chol 17 ± 2 44 ± 2 0.20 -9 ± 1 ND ND
 (2:1)   (<0.10)    
4 ePC:SA 22 ± 5 61 ± 1 0.16 -9 ± 1 ND ND
 (9.5:0.5)   (<0.15)    
Results฀are฀expressed฀as฀mean฀±฀SD.
Initial฀lipid฀concentration฀[Lip]i:฀20฀μmol/ml;฀Initial฀Cuphen฀[Cuphen]i:฀500฀nmol/ml;฀ePC฀transition฀temperature:฀-6°C฀[55].
I.E.฀(%):฀Incorporation฀eficiency:฀[(Cuphen/Lip)f]/[(Cuphen/Lip)i]฀×฀100;฀Ø:฀Mean฀size฀of฀liposomes;฀PI:฀Polydispersity฀index;฀Zeta฀Pot.:฀Zeta฀potential.
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Figure 5. Evaluation of Cuphen formulations effect on cell viability by ViaCount. (A) Cell populations obtained by Guava ViaCount 
flow cytometry after 72 h incubation of MNT-1 melanoma cells with different Cuphen concentrations. (B) Percentage of viable and 
dead cells. Results are expressed as mean ± SEM of at least three different experiments. Lipid compositions: Formulation 1 – ePC; 
Formulations 2 – ePC:Chol:PEG. 
*p < 0.001 from control; **p < 0.001 from the respective free form concentration.
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Figure 6. Hemolytic activity of Cuphen formulations 
in human RBC. Tested Cuphen concentrations ranged 
from 1 to 200 μM. Lipid composition ePC:Chol:PEG.
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are reported in Table 2. The similar cellular viability 
behavior is reflected by the close cytotoxic profiles.
In general, when incorporated in liposomes, Cuphen 
was able to exert its cytotoxic effect with IC
50
 values 
in the low micromolar range (≤10 μM), but slightly 
higher than the compound alone (see Table 2). The 
slight increase in the observed IC
50
 values suggests 
that Cuphen remains incorporated in liposomes and, 
as such, is not immediately available to exert cyto-
toxic effects. Similar observations have been reported 
for other antitumor drugs [60]. As previously observed 
for the free form of the metallodrug, the efficacy of 
Cuphen liposomes must not only consider the IC
50
 
value (Table 2) but also the survival rates, reflect-
ing the extension of the cytotoxic effect. Our results 
allowed identifying the maintenance of survival rates, 
despite the liposomal formulation. In other words, one 
can represent the cell lines according to the survival 
rates in the following order: HaCaT>B16F10>MNT-
1>A431>C26 with survival rates ranging from 10 to 
40% for C26 and HaCaT cells, respectively. The high-
est cellular survival rate was obtained for the healthy 
skin cell line, following by the skin cancer cell lines. 
Accordingly, as the most sensitive cell line, one can 
identify the murine colon cancer cells
Guava ViaCount assay
The analysis on cell viability obtained by Guava 
ViaCount flow cytometry corroborates the cyto-
toxic behavior of the different Cuphen formulations 
observed with the MTS assay. After 72 h of incuba-
tion, both F1 and F2 showed similar effects to the free 
drug, inducing loss of cell viability by 80% (Figure 5). 
Thus, the Cuphen-liposome formulation maintained 
the potent apoptotic properties of the copper complex.
Hemolytic activity of Cuphen
The US FDA recommends that for excipients intended 
for injectable use, an in vitro hemolysis study should be 
performed at the intended concentration for iv. admin-
istration to test for hemolytic potential [61]. The in vitro 
hemolysis assay evaluates hemoglobin release in the 
plasma (as an indicator of red blood cell lysis) follow-
ing exposure to a test agent [41]. In the present work, the 
hemolytic activity against RBCs was used as a marker 
of a general membrane toxicity effect of Cuphen. In 
this assay, the percentage of hemolysis of Cuphen in 
free form or incorporated in liposomes was tested for 
concentrations up to 200 μM. As shown in Figure 6, 
the hemolysis was always below 4% ensuring the safety 
of these formulations for iv. administration. Moreover, 
the hemolysis caused by the liposome formulation was 
substantially reduced with respect to the free Cuphen.
In vivo toxicity of Cuphen
Since copper-based compounds may present side 
effects in vivo, before testing the therapeutic effect of 
Cuphen liposomes, some preliminary toxicity stud-
ies were performed. From the best of our knowledge, 
this is the first report dealing with in vivo administra-
tion of Cuphen liposomes. Thus, based on the above-
mentioned studies showing that Cuphen do not elicit 
hemolytic activity up to 200 μM, two groups of mice 
received iv. injections of the metallodrug in the free 
form or incorporated in liposomes, for 1 week. All 
mice groups showed normal behavior and body weight 
as monitored on a daily basis. At the end of injections 
schedule, mice were sacrificed and organs of interest 
collected and weighted. Table 4 shows the tissue index 
Table 4. Tissue indexes of mice after iv. administration of Cuphen in free and liposomal forms.
Group of mice Tissue index
 Liver Spleen Kidney Lung Heart
Naive 22.8 ± 0.7 6.1 ± 0.3 13.2 ± 0.3 8.4 ± 0.4 7.0 ± 0.4
Free Cuphen 22.0 ± 0.7 5.7 ± 0.2 13.1 ± 0.4 7.6 ± 0.2 7.3 ± 0.1
LIP Cuphen 22.1 ± 0.4 6.7 ± 0.6 13.5 ± 0.5 7.7 ± 0.3 7.0 ± 0.1
Mice฀received฀formulations฀at฀a฀dose฀of฀1.5฀mg/kg฀of฀body฀weight,฀three-times฀a฀week฀during฀1฀week.
Lipid฀composition฀ePC:Chol:PEG.฀Results฀are฀expressed฀as฀the฀mean฀±฀SD฀of฀ive฀mice฀per฀group.
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for the analyzed organs, namely the liver, spleen, kid-
ney, heart and lung of mice receiving Cuphen formu-
lation F2 in comparison with animals receiving free 
Cuphen and with naive mice, in other words, animals 
that did not receive any formulation. Tissue index 
allows the evaluation of changes in a specific organ 
that may occur related to the whole body weight. 
Organ weight changes have long been accepted as a 
sensitive indicator of chemically induced changes to 
organs [62]. In particular, liver, kidneys and spleen are 
considered the most valuable in different areas such 
as pharmaceutical, veterinary, chemical and food/
nutritional/consumer [62]. Results showed no statisti-
cal significant differences for the tissue indexes among 
the three groups of mice. The aspartate transaminase 
(AST) and the alanine transaminase (ALT) blood lev-
els and ratio were also determined, since these are two 
of the most reliable markers of hepatocellular injury or 
necrosis [63]. The results are shown in Table 5, proving 
that no toxic hepatic effects were observed following iv. 
injection of the Cuphen formulations.
It is also worth mentioning that in general, drug 
delivery systems in particular liposomes have highly 
contributed in cancer treatment [29,30]. Liposomal for-
mulations, specifically those containing PEG in the 
lipid composition, present several advantages over the 
administration of a free molecule. The iv. administra-
tion of PEG liposomes results in a prolonged blood cir-
culation, reduced interaction with plasma proteins and 
thus allowing a preferential accumulation in tumor tis-
sues. Due to the leaky nature of the tumor-associated 
blood vessels, liposomes translocate across the capil-
lary endothelium and enter in the interstitial space. 
The size of the gaps between the endothelial cells lin-
ing the tumor capillaries ranges from 100 to 780 nm 
depending on the cancer type, as opposed to that in a 
typical normal endothelium of 5–10 nm [64]. In addi-
tion, solid tumors are characterized by an inadequate 
lymphatic drainage. Therefore, there is limited circu-
latory recovery of the extravasated molecules, result-
ing in the accumulation of liposomal formulations in 
the tumor microenvironment. Unlike liposomes, low-
molecular-weight drugs are not retained in the tumor 
site for a longer period of time, since they re-enter 
the circulation primarily via diffusion [65]. It is clear 
the importance of using liposomal formulations of 
Cuphen in particular those containing PEG that pres-
ent long blood circulation times and consequently high 
 possibility to extravasate to solid tumors.
Conclusion
In the present work, the Cu(II) complex Cuphen, 
an AQP3 inhibitor, showed potent cytotoxic effects 
toward different tumor cell lines. Various reports indi-
cate that the high reactivity of Cu(II) ions in vitro may 
have a high damage potential. Therefore, Cuphen was 
efficiently incorporated in long circulating liposomes 
and kept the properties resulting from being a potent 
apoptotic inducer.
The lack of in vivo toxicity after parenteral admin-
istration renders this nanoformulation attractive to be 
used against melanoma and colon cancer taking into 
account the preferential extravasation and accumu-
lation of PEG liposomes in solid tumors. The same 
strategy can be easily adapted for other metallodrugs 
such as the gold(III) complex Auphen that shows even 
higher AQP3 inhibition ability [14]. Further studies are 
certainly necessary to validate inhibition of AQP3 as 
the main target responsible for the anticancer effects 
of Cuphen and similar metal compounds, as well as 
to assess Cuphen anticancer activity in vivo. As a mat-
ter of fact, various biomolecules other than AQPs, and 
different cellular pathways were reported to be likely 
targets for different families of cytotoxic copper(II) 
complexes [22]. At this stage of our investigation, we 
believe that inhibition of AQPs may still occur extra-
cellularly upon release of Cuphen from the liposome 
formulation, being the main function of the formula-
tion not necessarily to increase the uptake of Cuphen 
in cancer cells, but to enhance its stability as well as 
its accumulation in cancerous tissues via the enhanced 
permeability and retention (EPR) effect.
Future perspective
Clinical and preclinical studies evidence the overex-
pression of AQPs in a high number of cancers. In this 
Table 5. Aspartate transaminase and alanine transaminase ratio from plasma samples of mice after 
iv. administration of Cuphen in free and liposomal forms.
Group of mice AST/ALT ratio
Naive 0.6 ± 0.1
Free Cuphen 0.8 ± 0.2
LIP Cuphen 0.8 ± 0.2
LIP฀Cuphen:฀lipid฀composition฀ePC:Chol:PEG.฀Results฀are฀expressed฀as฀the฀mean฀±฀SD฀of฀ive฀mice฀per฀group.
ALT:฀Alanine฀transaminase;฀AST:฀Aspartate฀transaminase.
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sense, the development of selective AQP inhibitors rep-
resents a new therapeutic strategy in cancer treatment. 
Metallodrugs of copper and gold (as those included 
in the present work) are potential candidates to fulfill 
this need. However, to promote a preferential targeting 
to tumor sites, the design and development of novel 
technologies based on nanostructured materials, such 
as liposomes, acting mainly as vectors for metallodrug 
delivery or simply as protectors of the complexes for 
amplifying their activities and reducing their degrada-
tion, constitutes a stimulating research area. We expect 
that these strategies can raise the interest of the phar-
maceutical companies allowing the introduction of 
novel metallodrugs  nanoformulations in the market as 
anticancer chemotherapeutics.
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Executive summary
•฀ Cuphen is a potent copper-based aquaporin inhibitor with cytotoxic effect against melanoma and colon 
cancer cell lines, with IC
50
 values in the micromolar range.
•฀ Cuphen was successfully incorporated into long circulating liposomes following a suitable selection of lipid 
compositions.
•฀ The cytotoxic properties of Cuphen after incorporation in liposomes were preserved.
•฀ Cuphen liposomes exhibit appropriate characteristics for in vivo administration, thus allowing the in vivo 
targeting and accumulation in tumor sites.
•฀ Cuphen liposomes did not elicit hemolytic activity.
•฀ Cuphen liposomes did not display toxicity after in vivo administration.
•฀ Cuphen-PEG liposomes may be considered a very attractive nanoformulation with therapeutic potential 
against melanoma and colon cancer due to their preferential extravasation and accumulation in solid tumors.
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